Pregabalin + Pregabalin
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Epilepsy, Complex Partial
Conditions
Epilepsy, Complex Partial
Trial Timeline
Apr 1, 2010 → Jul 1, 2014
NCT ID
NCT01128712About Pregabalin + Pregabalin
Pregabalin + Pregabalin is a approved stage product being developed by Pfizer for Epilepsy, Complex Partial. The current trial status is terminated. This product is registered under clinical trial identifier NCT01128712. Target conditions include Epilepsy, Complex Partial.
What happened to similar drugs?
20 of 20 similar drugs in Epilepsy, Complex Partial were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01128712 | Approved | Terminated |
Competing Products
20 competing products in Epilepsy, Complex Partial
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| perampanel | Eisai | Phase 2 | 35 |
| Lacosamide | UCB | Phase 3 | 40 |
| Zonisamide + Placebo | Eisai | Phase 3 | 32 |
| Zonegran | Eisai | Approved | 35 |
| perampanel + perampanel | Eisai | Phase 1 | 29 |
| Perampanel + Placebo | Eisai | Approved | 35 |
| perampanel | Eisai | Approved | 35 |
| E2007 + Placebo | Eisai | Phase 2 | 35 |
| Placebo + Rufinamide | Eisai | Phase 3 | 40 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 35 |
| Perampanel Oral Tablet | Eisai | Approved | 43 |
| perampanel | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Zonisamide + Carbamazepine | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Approved | 43 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 29 |
| Perampanel | Eisai | Phase 2 | 35 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| zonisamide low dose group + zonisamide high dose group | Eisai | Approved | 43 |
| E2007 + E2007 + Placebo | Eisai | Phase 2 | 35 |